Search clinical trials for: UE2343

Total 6 results

University of Edinburgh
Wellcome Trust; Simbec Research

Completed

A Phase I Study of Oral UE2343 in Healthy Subjects (UE2343)

Healthy

United Kingdom
Actinogen Medical
Novotech (Australia) Pty Limited; Linear Clinical Research

Completed

Phase I MAD, Fed-Fasted, CSF Study of UE2343 in Healthy Subjects

Healthy Volunteers

Australia
Actinogen Medical
ICON plc

Completed

Xanamem™ in Healthy Elderly Subjects (XanaHES)

Cognitive Function | Peripheral Neuropathy | Electrocardiography | Central Nervous System | Safety | Healthy Ageing | Cortisol | Cerebrospinal Fluid | Small Fibre Neuropathy

Australia
Actinogen Medical

Recruiting

Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease (XanaMIA)

Alzheimer Disease | Dementia, Mild | Dementia Moderate

Australia
Actinogen Medical
AXIOM Real Time Metrics

Active, not recruiting

Xanamem® in Adults With Major Depressive Disorder and Impaired Cognition (XanaCIDD)

Cognitive Impairment | Major Depressive Disorder | MDD

Australia, United Kingdom
Actinogen Medical
ICON Clinical Research

Completed

A Phase II Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to AD (XanADu) (XanADu)

Dementia, Alzheimer Type

United States, Australia, United Kingdom

3

Subscribe